Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082439 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma
A Phase 2 study of Colorectal Adenocarcinoma Metastatic in the Liver, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT07082439: Recruiting Phase 2 study of Colorectal Adenocarcinoma Metastatic in the Liver, sponsored by Abramson Cancer Center at Penn Medicine.
NCT07082439 is a Phase 2 study of Colorectal Adenocarcinoma Metastatic in the Liver that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 27 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07082439, a Phase 2 study of Colorectal Adenocarcinoma Metastatic in the Liver, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
Primary Outcome
Proportion of patients with best response as complete response (CR) or PR (partial response) using RECIST v. 1.1.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Odetiglucan
Study Locations (1)
Pennsylvania
- Abramson Cancer Center at the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
What NCT07082439 shows while recruiting
NCT07082439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Colorectal Adenocarcinoma Metastatic in the Liver appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07082439 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07082439 about?
NCT07082439 is a clinical study titled "Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma". This study will evaluate the safety and effectiveness of the combination of pembrolizumab and odetiglucan in patients with metastatic colorectal cancer that is predominantly in the liver.
What is the current status of trial NCT07082439?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2025-09-10. Estimated completion is 2029-09.
What conditions does trial NCT07082439 study?
This clinical trial studies the following conditions: Colorectal Adenocarcinoma Metastatic in the Liver.
What interventions are being tested in trial NCT07082439?
The interventions under investigation include: Pembrolizumab (DRUG), Odetiglucan (DRUG).
Who is sponsoring clinical trial NCT07082439?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082439 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07082439's enrollment target sits among peer trials
27 1697th of 2000 higher than 294 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI